Diarrhea is a common and clinically significant complication in patients with advanced medullary thyroid carcinoma, and its management is an important part of overall care in this setting.
Diarrhea occurs most frequently in patients with advanced disease and hepatic metastases. It is a common occurrence in the setting of markedly elevated serum calcitonin levels, and addressing it requires a structured, evidence-based approach.
Initial management centres on antimotility agents as first-line therapy. The full protocol — specifying which agents are appropriate, how they are sequenced, and when to consider further steps — is available in the complete structured regimen.
DOI: 10.1089/thy.2014.0335
Diarrhea occurs most frequently in patients with advanced disease and hepatic metastases.
Diarrhea is a common occurrence in patients with advanced MTC and markedly elevated serum Ctn levels.
The antimotility agents loperamide, diphenoxylate/atropine, or codeine have minimal side effects and should be used as first-line therapy.
Patients with advanced MTC and diarrhea should be treated initially with antimotility agents.
View source ↗